POD24 in MZL: a means to an end or an end point in itself?

In this issue of Blood, Luminari et al demonstrate that patients with marginal zone lymphoma (MZL) who experience early progression (progression of disease at 24 months [POD24]) have poor survival. Overall survival after POD24 was 53% at 3 years, a stark contrast to the 95% 5-year survival rate from diagnosis in patients without early progression. These results extend the seminal study in follicular lymphoma (FL) from the National LymphoCare Study by Casulo et al to include indolent nonfollicular B-cell lymphomas (INFLs).